Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes

    ... myelodysplastic syndromes (MDS) treated with lenalidomide ; such modifications are recommended to sustain therapy and ... case-control study was to determine the relationship between lenalidomide dose modification (DM), duration of lenalidomide therapy (DOT), ...

    Research Article last updated 11/08/2017 - 9:12am.

  2. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

    ... disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion -dependent anemia . Although lenalidomide has erythropoeitic promoting activity in MDS without del(5q) ... to biologically separate drug effects. In del(5q) MDS, lenalidomide suppresses the malignant clone to restore effective ...

    Research Article last updated 10/23/2017 - 10:58am.

  3. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

    ... disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion -dependent anemia . Although lenalidomide has erythropoeitic promoting activity in MDS without del(5q) ... to biologically separate drug effects. In del(5q) MDS, lenalidomide suppresses the malignant clone to restore effective ...

    Research Article last updated 10/02/2017 - 9:54am.

  4. Lenalidomide

    ... syndromes (MDS) Lenalidomide is a capsule that is taken by mouth. It is approved for ... with a broader range of MDS patients. For some MDS patients, lenalidomide can improve anemia and reduce or eliminate the need for ...

    Drug last updated 03/24/2016 - 12:32pm.

  5. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

    ... 14, 2017 While lenalidomide (LEN) is the standard of care for the lower-risk ... 5q deletion and to analyze their outcome after failure of lenalidomide. The median survival following LEN failure was 23 months. We ...

    Research Article last updated 07/11/2017 - 10:11am.

  6. Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes

    ... and response to erythroid stimulating agents or lenalidomide has not been investigated. The HepG2 hepatoma cell line was ... (125 prior to erythroid stimulating agents and 186 prior to lenalidomide). Serum concentrations of S100A9, S100A8, TNFα, IL1β and Epo ...

    Research Article last updated 10/20/2017 - 9:16am.

  7. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

    ... (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates (ORRs) ... on days 1 to 7 of a 28-day cycle); azacitidine plus lenalidomide (10 mg/day on days 1 to 21); or azacitidine plus vorinostat (300 ...

    Research Article last updated 05/22/2017 - 10:52am.

  8. Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

    ... of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results ...

    Research Article last updated 05/22/2017 - 11:42am.

  9. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

    ... ( azacitidine , decitabine , or lenalidomide ) timing (≤ 3 vs.>3months from start of TD) on the likelihood ...

    Research Article last updated 09/13/2017 - 8:58am.

  10. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications

    ... to AML among patients with lower-risk MDS (LR-MDS). Lenalidomide is the drug with the most impressive clinical activity in the ... independence and cytogenetic responses. Furthermore, lenalidomide delays progression to AML and prolongs survival among responders. ...

    Research Article last updated 02/21/2017 - 9:34am.